Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005–2010: a population-based study from the National Swedish Kidney Cancer Register

Thorstenson, Andreas; Bergman, Maud; Scherman-Plogell, Ann-Helén; Hosseinnia, Soheila; Ljungberg, Börje; Adolfsson, Jan; Lundstam, Sven

doi:10.3109/21681805.2013.864698

Cited by 91 publications

(69 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In line with the present results, a constant decrease in mean diameter of the renal tumor from 70 mm (in 2005) to 55 mm (in 2013) was demonstrated in the National Swedish Renal Cancer Register [13]. The stage reduction by time seen in our study correlated with a decrease in clear-cell and an increase in papillary histologic type.…”

Section: Discussionsupporting

confidence: 79%

“…Similarly, in the SEER data from 2000 to 2005, stage I was more frequent in papillary RCC (69.9%) than in clear-cell RCC (60.5%) [19]. The percentage of metastases of RCC at diagnosis has decreased to 14-15% in the recent population-based reports [13,20], which is quite similar to the 12% found in the present cohort. To date, there is no evidence from randomized studies to support the use of CN in the era of targeted therapy [21].…”

Section: Discussionsupporting

confidence: 76%

“…Indeed, the use of nephrectomy in patients with metastatic RCC has declined in many countries to 33-34% [22,23]. In contrast, the relatively liberal use of CN in our cohort (54%) is in line with a recent Swedish register study, in which 55% of metastatic patients received CN [13]. During the study period, no clear benefit for adjuvant treatment was shown, and adjuvant treatment was therefore not given in our patient population.…”

Section: Discussioncontrasting

confidence: 46%

“…However, this change in paradigm is not necessarily reflected in the public registry data. Indeed, in the National Swedish Renal Cancer Register [13], the Norwegian cancer register [14], and the Surveillance, Epidemiology, and End Results (SEER) database [15], the focus is still on patients with histologically verified RCC.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Evolving Clinical Picture of Renal Cell Carcinoma: A Population-Based Study from Helsinki

et al. 2019

View full text Add to dashboard Cite

Background: There is a lack of detailed population-based data for renal cell carcinoma (RCC). Objectives: The study aimed to examine the contemporary changes in the clinical picture and treatment of RCC. Methods: A total of 1,719 consecutive patients living in the Helsinki metropolitan area with a solid or cystic renal mass (Bosniak 3–4) ≥10 mm were identified. Data from medical records was evaluated for clinical characteristics and treatments in the periods I (2006–2008), II (2009–2011), III (2012–2014), and IV (2015–2016). Results: The proportions of patients with comorbidities (Charlson index ≥2) and frailty (Eastern Co-operative Oncology Group classification ≥2) increased significantly during the study period. The percentage of clinical stage I patients, cystic tumors and use of needle biopsies increased significantly. Use of observation increased from 9% (I) to 32% (IV; p < 0.001). First-line oncological treatments within 6 months were given to 47% of 262 patients with metastases and cytoreductive nephrectomy (CN) was delivered to 54% of those patients. Conclusions: The size of renal tumors continued to decrease, while the percentage of patients with significant comorbidity or frailty increased. Active surveillance emerged as the initial strategy. Tyrosine kinase inhibitors with CN remained the primary option in patients with metastatic RCC.

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Discussionsupporting

confidence: 76%

Section: Discussioncontrasting

confidence: 46%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Evolving Clinical Picture of Renal Cell Carcinoma: A Population-Based Study from Helsinki

et al. 2019

View full text Add to dashboard Cite

show abstract

“…So far, only comprehensive data from Italy and France [8] and, recently, from Sweden [9], are available. However, due to systemic differences in healthcare patterns, these numbers might only marginally reflect utilization trends elsewhere in Europe.…”

Section: Introductionmentioning

confidence: 99%

The Adoption of Nephron-Sparing Surgery in Europe - A Trend Analysis in Two Referral Centers from Austria and Germany

Meyer

Hansen²,

Becker³

et al. 2015

Urol Int

View full text Add to dashboard Cite

Objective: To compare the trends of partial nephrectomy (PN) and radical nephrectomy (RN) in 2 European tertiary referral centers with regards to guideline changes. Materials and Methods: A total of 1,573 patients who underwent RN or PN for localized (≤T2) renal cell carcinoma (RCC) were included. Logistic regression analyses assessed the predictors of PN and laparoscopy over time. Results: Out of the total, 1,013 patients (65.6%) were treated with RN and 560 patients (34.4 %) with PN. Also, 1,233 patients (80%) had open surgery whereas 340 patients (22%) were treated with a laparoscopic approach. Laparoscopic RN and PN were performed in 216 (13.7%) and 124 (7.8%) patients, respectively. T1b tumors were 73% less likely (p < 0.001) to be treated with PN compared to T1a tumors. The odds of undergoing PN or laparoscopy in 2008-2010 relative to 2000-2001 were 6.5-fold (p < 0.001) and 36-fold higher (p < 0.001), respectively. Conclusions: Tumor size and year of surgery are independent predictors of PN in our cohort. Our data exemplify the adoption of PN for RCC in tertiary care centers in Austria and Germany in line with implemented guideline changes. The utilization of PN has increased over time regardless of surgical approach. Further studies need to address the use of robot-assisted surgery and care in community hospitals.

show abstract

Alcohol consumption and the risk of renal cancers in the European prospective investigation into cancer and nutrition (EPIC)

Wozniak

Brennan

Brenner

et al. 2015

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Epidemiologic studies have reported that moderate alcohol consumption is inversely associated with the risk of renal cancer. However, there is no information available on the associations in renal cancer subsites. From 1992 through to 2010, 477,325 men and women in the European Prospective Investigation into Cancer and Nutrition cohort were followed for incident renal cancers (n = 931). Baseline and lifetime alcohol consumption was assessed by country-specific, validated dietary questionnaires. Information on past alcohol consumption was collected by lifestyle questionnaires. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated from Cox proportional hazard models. In multivariate analysis, total alcohol consumption at baseline was inversely associated with renal cancer; the HR and 95% CI for the increasing categories of total alcohol consumption at recruitment versus the light drinkers category were 0.78 (0.62–0.99), 0.82 (0.64–1.04), 0.70 (0.55–0.90), 0.91 (0.63–1.30), respectively, (ptrend = 0.001). A similar relationship was observed for average lifetime alcohol consumption and for all renal cancer subsites combined or for renal parenchyma subsite. The trend was not observed in hypertensive individuals and not significant in smokers. In conclusion, moderate alcohol consumption was associated with a decreased risk of renal cancer

show abstract

Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005–2010: a population-based study from the National Swedish Kidney Cancer Register

Cited by 91 publications

References 15 publications

Evolving Clinical Picture of Renal Cell Carcinoma: A Population-Based Study from Helsinki

Evolving Clinical Picture of Renal Cell Carcinoma: A Population-Based Study from Helsinki

The Adoption of Nephron-Sparing Surgery in Europe - A Trend Analysis in Two Referral Centers from Austria and Germany

Alcohol consumption and the risk of renal cancers in the European prospective investigation into cancer and nutrition (EPIC)

Contact Info

Product

Resources

About